ASCO® 2024 Summary: "Gynecologic Oncology Updates"

2024 ASCO® Annual Meeting Insights Hub

R. Salani

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

Recent FDA Indications in Endometrial Cancers

Brian Slomovitz

ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Adv…

2024 ESMO Annual Meeting Insights Hub

B. Monk

ESMO 2024 Summary: dMMR Advanced/Recurrent Endometrial Cancer - Adva…

2024 ESMO Annual Meeting Insights Hub

M. Raza Mirza

ASCO® 2024 Summary: "Gynecological Cancers Highlights"

2024 ASCO® Annual Meeting Insights Hub

M. Raza Mirza

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Year in Review 2024 - Endometrial Cancer

Mansoor Raza Mirza

ESMO 2024 Insights: Pembro or Placebo in Combination With Adjuvant C…

2024 ESMO Annual Meeting Insights Hub

B. Slomovitz

Gynecologic Oncology Updates: Expert Perspective on Key Trial Findin…

Yale Cancer Center

E. Ratner

Endometrial Cancer: The Current Treatment Landscape

Hope Cottrill

ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagn…

2024 ESMO Annual Meeting Insights Hub

B. Monk

Year in Review 2024 - Ovarian Cancer

Oncology 2024 Year in Review

E. Crane

SGO 2024 Endometrial Cancer Highlights

Insights from 2024 SGO Annual Meeting

P. Binder

ESMO 2024 Insights: PRIMA Trial - Newly Diagnosed Advanced Ovarian C…

ecancer

A. González-Martín

ESMO 2024 Insights: Mirvetuximab Soravtansine-gynx (MIRV) in Platinu…

2024 ESMO Annual Meeting Insights Hub

A. Secord

Cancer Screening Molecular Tools

Fengting Yan

Durvalumab/C/T as 1L Treatment for dMMR Advanced Endometrial Cancer:…

Dana Chase

Management of Recurrent Ovarian Clear Cell Carcinoma

David Tan

Addressing the Critical Gaps in Relapsed Ovarian Cancer Management

Michael Birrer